Chest
-
Randomized Controlled Trial
Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension.
There are currently no licensed medical therapies for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). ⋯ Although this pilot study was insufficiently powered to test the primary end point, it did suggest beneficial effects in favor of sildenafil in several secondary end points at both 3 months and 12 months. Further larger-scale trials of sildenafil in inoperable CTEPH are required to confirm these findings and potentially increase the treatment options available for this devastating disease.